Marksans Pharma reported a significant 63% increase in Q4 net profit, reaching ₹148 crore, thanks to an impressive 21% revenue growth that took the total to ₹856 crore. Additionally, EBITDA saw a robust 54% growth, hitting ₹195.3 crore.

Marksans Pharma has released its Q4 earnings, highlighting significant figures. Stay tuned for more details on the financial performance of this pharmaceutical company.

Marksans Pharma has announced their Q4 and full year financial results for 2025-26, with an unmodified auditor's opinion signaling a clean bill of health. The company's board proposed a final dividend of Rs. 0.90 per share, pending approval at the upcoming Annual General Meeting.

Marksans Pharma plans to enhance its store brand presence in the US market, aiming to double its over-the-counter (OTC) revenue as part of an effort to boost North American business.

Marksans Pharma has reported a significant 21% year-on-year increase in its Q4 revenue, reaching ₹8.6 billion, indicating robust growth in their business operations.

Marksans Pharma will convene a board meeting on May 26, 2026, to discuss and approve the financial results for FY26 and consider the dividend recommendation for the fiscal year FY25-26. Trading activity for the company will be suspended until May 28, 2026.

Foreign institutional investors (FIIs) have shown increased interest in the Indian pharmaceutical sector, as evidenced by their growth in stakes for companies like Shilpa Medicare, Marksans Pharma, and Jagsonpal Pharma during Q1 FY26. Notably, Shilpa Medicare is expanding its presence in Latin America, Marksans Pharma has secured FDA approvals, while Jagsonpal Pharma focuses on women's health and maintaining financial discipline.

Marksans Pharma has received FDA approval for its Benzonatate capsules, enabling them to introduce this medication into the U.S. market with two available strengths: 100 mg and 200 mg.

Marksans Pharma has secured approval from the US FDA to market Benzonatate Capsules, a treatment for coughs and respiratory infections in the United States. This development expands their reach into the American market.

Marksans Pharma experienced a 7.9% surge in shares due to USFDA approval for a generic version of Tessalon (Benzonatate Capsules), previously owned by Pfizer. The company's Q3FY26 net profit increased significantly to ₹11,320.2 crore, with revenue growth of 10.6% YoY, attributed to strong execution and favorable market conditions.

Marksans Pharma has received U.S. FDA approval for Benzonatate Capsules, expanding their product portfolio in the American market. This approval could potentially increase their market presence and revenue stream in the US pharmaceutical sector.